Free software to analyse the clinical relevance of drug interactions with antiretroviral agents (SIMARV®) in patients with HIV/AIDS

Giraldo, Newar; Amariles, Pedro; Monsalve, Mauricio; Faus, María José

doi:10.1016/j.sapharm.2016.09.002

Cited by 3 publications

(2 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The method for assessing the clinical relevance of drug interactions used in this review was similar to that used in previous reviews [5][6][7][8]; therefore, these results were useful in updating and synthesizing the previous identified information regarding ARV drug interactions. Thereby, the 291 drug interaction pairs systematically reported for the first time should be used to update the mobile application for analyzing the clinical relevance of ARV drug interactions (InterApp ARV) [10], which is an evolution of the SIMARV ® software [9]. The application is freely accessible and can be downloaded for Android devices from the Play Store (https://play.google.com/store/apps/details?id=co.com.pypudea.interapparv accessed on 25 July 2023).…”

Section: Discussionmentioning

confidence: 99%

“…However, due to the commercialization of new ARVs, updates to guidelines and expert recommendations and, mainly, both the identification and reporting of new clinically relevant drug interactions or the generation of new knowledge about drug interactions systematically reported previously, this information should be periodically updated. In addition, in 2017, a free software to facilitate the identification and assessment of the clinical relevance of ARV drug interactions (SIMARV ® ) was developed [9]; then, a free mobile version (InterApp-ARV) was developed and is available for mobile phones and tablets [10]. The development of both SIMARV ® and InterApp ARV, used as a graphic reference the free software developed by the University of Liverpool (https://www.hiv-druginteractions.org/ accessed on 25 July 2023), is considered as the most used online source of DDI in HIV [11].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical Relevance of Drug Interactions in People Living with Human Immunodeficiency Virus on Antiretroviral Therapy—Update 2022: Systematic Review

Amariles,

Rivera-Cadavid,

Ceballos

2023

Pharmaceutics

Self Cite

View full text Add to dashboard Cite

Background: The clinical outcomes of antiretroviral drugs may be modified through drug interactions; thus, it is important to update the drug interactions in people living with HIV (PLHIV). Aim: To update clinically relevant drug interactions in PLHIV on antiretroviral therapy with novel drug interactions published from 2017 to 2022. Methods: A systematic review in Medline/PubMed database from July 2017 to December 2022 using the Mesh terms antiretroviral agents and drug interactions or herb–drug interactions or food–drug interactions. Publications with drug interactions in humans, in English or Spanish, and with full-text access were retrieved. The clinical relevance of drug interactions was grouped into five levels according to the gravity and probability of occurrence. Results: A total of 366 articles were identified, with 219 (including 87 citation lists) were included, which allowed for the identification of 471 drug interaction pairs; among them, 291 were systematically reported for the first time. In total 42 (14.4%) and 137 (47.1%) were level one and two, respectively, and 233 (80.1%) pairs were explained with the pharmacokinetic mechanism. Among these 291 pairs, protease inhibitors (PIs) and ritonavir/cobicistat-boosted PIs, as well as integrase strand transfer inhibitors (InSTIs), with 70 (24.1%) and 65 (22.3%) drug interaction pairs of levels one and two, respectively, were more frequent. Conclusions: In PLHIV on antiretroviral therapy, we identify 291 drug interaction pairs systematically reported for the first time, with 179 (61.5%) being assessed as clinically relevant (levels one and two). The pharmacokinetic mechanism was the most frequently identified. PIs, ritonavir/cobicistat-boosted PIs, and InSTIs were the antiretroviral groups with the highest number of clinically relevant drug interaction pairs (levels one and two).

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Clinical Relevance of Drug Interactions in People Living with Human Immunodeficiency Virus on Antiretroviral Therapy—Update 2022: Systematic Review

Amariles,

Rivera-Cadavid,

Ceballos

2023

Pharmaceutics

Self Cite

View full text Add to dashboard Cite

show abstract

Free InterApp ARV: The subsequent version of SIMARV® to analyse the clinical relevance of drug interactions with antiretroviral agents in patients with HIV/AIDS

Amariles

Giraldo

Madrigal-Cadavid

et al. 2019

Research in Social and Administrative Pharmacy

View full text Add to dashboard Cite

Clinical Relevance of Drug Interactions in People Living with Human Immunodeficiency Virus on Antiretroviral Therapy - Update 2022: Systematic Review

Amariles¹,

Rivera-Cadavid²,

Ceballos³

2023

Preprint

View full text Add to dashboard Cite

Background: The clinical outcomes of antiretroviral drugs may be modified by drug interactions; thus, it is important to update the drug interactions in people living with HIV. Aim: To update clinically relevant drug interactions in people living with HIV on antiretroviral therapy. Methods: A systematic review in Medline/PubMed database from July 2017 to December 2022, using the Mesh terms: Anti-retroviral agents and drug interactions or herb-drug interactions or food-drug interactions. Publications with drug interactions in humans, in English or Spanish, and with full text were retrieved. The clinical relevance of drug interaction was grouped into 5 levels according to gravity and probability of occurrence. Results: 361 articles were identified and 148 were included, which allowed the identification of 894 drug interaction pairs. Among these 894 drug pairs, 355 have not been identified previously; and 89 (25.1%) and 72 (20.2%) were of levels 1 and 2, respectively. In addition, for 197 (55.5%) pairs the mechanism was pharmacokinetic. The non-nucleoside reverse transcriptase inhibitors (NNRTIs) and the protease inhibitors (PIs) with 91 (25.6%) and 76 (21.4%) pairs, respectively were more frequent. Conclusions: In people living with HIV on antiretroviral therapy, we identify 355 new drug interaction pairs, of them 161 (45.3%) are assessed as levels 1 and 2 and thus, clinically relevant; a figure that is lower compared to 2014-2107 update. The pharmacokinetic mechanism is the most frequently identified. The non-nucleoside reverse transcriptase inhibitors (NNRTIs) and the protease inhibitors (PIs) are the antiretroviral groups with the highest number of clinically relevant drug interactions.

show abstract

Free software to analyse the clinical relevance of drug interactions with antiretroviral agents (SIMARV®) in patients with HIV/AIDS

Cited by 3 publications

References 31 publications

Clinical Relevance of Drug Interactions in People Living with Human Immunodeficiency Virus on Antiretroviral Therapy—Update 2022: Systematic Review

Clinical Relevance of Drug Interactions in People Living with Human Immunodeficiency Virus on Antiretroviral Therapy—Update 2022: Systematic Review

Free InterApp ARV: The subsequent version of SIMARV® to analyse the clinical relevance of drug interactions with antiretroviral agents in patients with HIV/AIDS

Clinical Relevance of Drug Interactions in People Living with Human Immunodeficiency Virus on Antiretroviral Therapy - Update 2022: Systematic Review

Contact Info

Product

Resources

About